Reviewer’s report

Title: Drugs discontinuation before contrast procedures and the effect on acute kidney injury and other clinical outcomes: a systematic review protocol

Version: 0 Date: 24 Oct 2017

Reviewer: Oleksa Rewa

Reviewer’s report:

This is a well written and timely review examining the evidence for withholding certain medications around the time of contrast injection for the development of AKI. It will greatly serve to inform guidelines regarding CI-AKI. It's timing is important as the composition of IV contrast has changed recently, and previous factors which may have increased the risk of AKI may be different than previously.

I do however have several comments for the authors:

1. 1. While considering RRT as an important outcome, this may not be clinically achievable. You have mentioned that you will be assessing renal outcomes. Is it worth specifying that you will consider specific AKI stage progression (i.e., progression to AKI stage II or III without need of RRT) as an additional outcome?

2. As an additional outcome, if NSAIDs are discontinued, would you consider pain or alternative pain regiments as an outcome?

3. Would it be worth conducting an a priori subgroup analysis of outcomes in low and iso-osmolar contrast?

4. Would it be worth conducting an a priori subgroup analysis of cardiac angiography vs. other forms of contrast?

5. Could you provide further detail on the grey literature search?

I think provided the authors can provide answers to the above questions, this article is suitable for publication.

Thank you for the opportunity to review your manuscript.

Level of interest

Please indicate how interesting you found the manuscript:

An article of importance in its field that should be highlighted to relevant networks
Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.